et al. The natural history of multiple sclerosis: a geographically based study. I. Clinical course and disability. Brain 1989; 112(Pt 1): 133–46.
et al. Human TH17 lymphocytes promote blood-brain barrier disruption and central nervous system inflammation. Nat Med 2007; 13: 1173–5.
B cells and antibodies in CNS demyelinating disease. J Neuroimmunol 2001; 112: 1–14.
, , .
Double-masked trial of azathioprine in multiple sclerosis. British and Dutch multiple sclerosis azathioprine trial group. Lancet 1988; 2: 179–83.
et al. Overview of azathioprine treatment in multiple sclerosis. Lancet 1991; 338: 1051–5.
et al. Cyclophosphamide for multiple sclerosis. Cochrane Database Syst Rev. 2007, Issue 1: CD002819.
et al. Comparative pharmacokinetics and pharmacodynamics of two recombinant human interferon beta-1a (IFN beta-1a) products administered intramuscularly in healthy male and female volunteers. Pharm Res 1997; 14: 546–9.
Mechanisms of interferon beta action in multiple sclerosis. Mult Scler 1997; 3: 397–401.
et al. A pilot trial of Cop 1 in exacerbating-remitting multiple sclerosis. N Engl J Med 1987; 7: 408–14.
Glatiramer acetate (copaxone) therapy for multiple sclerosis. Pharmacol Ther 2003; 98: 245–55.
et al. Mechanisms of immunomodulation by glatiramer acetate. Neurology 2000; 55: 1704–14.
The IFNB Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 1993; 43: 655–61.
PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group. Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. Lancet 1998; 352: 1498–504.
et al., The Multiple Sclerosis Collaborative Research Group (MSCRG) Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. Ann Neurol 1996; 39: 285–94.
et al., The Copolymer 1 Multiple Sclerosis Study Group Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. Neurology 1995; 45: 1268–76.
et al. Efficacy of disease-modifying therapies in relapsing remitting multiple sclerosis: a systematic comparison. Eur Neurol 2008; 60: 1–11.
Immunomodulatory agents for the treatment of relapsing multiple sclerosis: a systematic review. Arch Intern Med 2002; 162: 2161–9.
, , .
et al. Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial. Lancet Neurol 2008; 7: 903–14.
et al. Interferon Beta-1b 500 mcg, Interferon Beta-1b 250 mcg and Glatiramer Acetate: Primary Outcomes of the Betaferon®/Betaseron® Efficacy Yielding Outcomes of a New Dose Study. Abstract from the American Academy of Neurology (AAN) 60th Annual Meeting. Chicago, IL, 2008. Abstract No: LBS.004. , ,
The IFNB Multiple Sclerosis Study Group and the University of British Columbia MS/MRI Analysis Group. Neutralizing antibodies during treatment of multiple sclerosis with interferon beta-1b: experience during the first three years. Neurology 1996; 47: 889–94.
et al., Multiple Sclerosis Collaborative Research Group (MSCRG). Incidence and significance of neutralizing antibodies to interferon beta-1a in multiple sclerosis. Neurology 1998; 50: 1266–72.
et al. Appearance and disappearance of neutralizing antibodies during interferon-beta therapy. Neurology 2005; 65: 33–9.
Neutralizing antibodies to interferon beta-1a and interferon beta-1b in MS patients are cross-reactive. Neurology 1998; 51: 1698–702.
et al. Monthly corticosteroids decrease neutralizing antibodies to IFNbeta1 b: a randomized trial in multiple sclerosis. J Neurol 2002; 249: 50–6.
et al. NORdic trial of oral Methylprednisolone as add-on therapy to Interferon beta-1a for treatment of relapsing-remitting Multiple Sclerosis (NORMIMS study): a randomised, placebo-controlled trial. Lancet Neurol 2009; 8: 519–29.
A Multi-Centre, Double Blind, Randomized, Placebo Controlled, Parallel Group Trial Investigating Methylprednisolone (MP) in Combination with Interferon-b-1a for the Treatment of Relapsing-Remitting Multiple Sclerosis (RRMS). Abstract from the 61st Annual Meeting of the American Academy of Neurologists (AAN). Seattle, WA, 2009. Abstract No: LB3.002. .
et al. ABN Guidelines for Treatment of Multiple Sclerosis with Beta-Interferon and Glatiramer acetate. London, UK: Association of British Neurologists, 2007. , ,
The Once Weekly Interferon for MS Study Group. Evidence of interferon beta-1a dose response in relapsing-remitting MS: the OWIMS Study. Neurology 1999; 53: 679–86.
Once weekly interferon beta for multiple sclerosis is superseded by higher and more frequent dosing. Int J Clin Pract Suppl 2002: 9–16.
et al. Humanization of a mouse antibody against human alpha-4 integrin: a potential therapeutic for the treatment of multiple sclerosis. Hum Antibodies 1997; 8: 3–16.
Blocking adhesion molecules as therapy for multiple sclerosis: natalizumab. Nat Rev Drug Discov 2005; 4: 510–8.
et al., The UK Antegren Study Group The effect of anti-alpha4 integrin antibody on brain lesion activity in MS. Neurology 1999; 53: 466–72.
et al. A controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2003; 348: 15–23.
et al. Randomized multicenter trial of natalizumab in acute MS relapses: clinical and MRI effects. Neurology 2004; 62: 2038–43.
et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2006; 354: 899–910.
et al. Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. N Engl J Med 2006; 354: 911–23.
et al. Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn’s disease. N Engl J Med 2005; 353: 362–8.
et al. Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy. N Engl J Med 2006; 354: 924–33.
Biogen Idec Inc. TYSABRI update; 2009 24th July. http://www.biogenidec.com/site/tysabri-information-center.html (accessed August 2009).
et al. Quantitative risk-benefit analysis of natalizumab. Neurology 2008; 71: 357–64.
et al. The incidence and significance of anti-natalizumab antibodies: results from AFFIRM and SENTINEL. Neurology 2007; 69: 1391–403.
Melanoma complicating treatment with natalizumab (Tysabri) for multiple sclerosis. J Neurol 2009; 256: 1771–2.
, , .
Mitoxantrone: a new anticancer drug with significant clinical activity. Ann Intern Med 1986; 105: 67–81.
et al. Therapeutic effect of mitoxantrone combined with methylprednisolone in multiple sclerosis: a randomised multicentre study of active disease using MRI and clinical criteria. J Neurol Neurosurg Psychiatry 1997; 62: 112–8.
et al. Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial. Lancet 2002; 360: 2018–25.
Selective immunomodulation by the antineoplastic agent mitoxantrone. I. Suppression of B lymphocyte function. J Immunol 1986; 137: 727–32.
, , .
Selective immunomodulation by the antineoplastic agent mitoxantrone. II. Nonspecific adherent suppressor cells derived from mitoxantrone-treated mice. J Immunol 1986; 136: 2747–54.
, , , .
Mechanism of action of mitoxantrone. Neurology 2004;63 (12 Suppl 6): S15–8.
et al. Suppression of demyelination by mitoxantrone. Int J Immunopharmacol 1991; 13: 923–30.
Suppression of acute and relapsing experimental allergic encephalomyelitis with mitoxantrone. Clin Immunol Immunopathol 1987; 45: 122–8.
, , , .
et al. Effect of mitoxantrone on MRI in progressive MS: results of the MIMS trial. Neurology 2005; 65: 690–5.
Mitoxantrone for multiple sclerosis in clinical practice. Neurology. 2004;63 (12 Suppl 6): S25–7.
, , .
Sequential maintenance treatment with glatiramer acetate after mitoxantrone is safe and can limit exposure to immunosuppression in very active, relapsing remitting multiple sclerosis. J Neurol 2006; 253: 1160–4.
, , , .
et al. Cardiac adverse effects associated with mitoxantrone (Novantrone) therapy in patients with MS. Neurology 2002; 59: 909–13.
Incidence of Acute Leukaemia in Multiple Sclerosis Patients Treated with Mitoxandrone: A Multicentre Retrospective Italian Study. Abstract from the 61st Annual Meeting of the American Academy of Neurology (AAN). Seattle, WA, 2009. .
et al. A study of therapy-related acute leukaemia after mitoxantrone therapy for multiple sclerosis. Mult Scler 2002; 8: 441–5.
et al. Mitoxantrone therapy in multiple sclerosis and acute leukaemia: a case report out of 644 treated patients. Mult Scler 2004; 10: 472–4.
et al. CAMPATH-IH in multiple sclerosis. Mult Scler 1996; 1: 357–65.
Campath-1H treatment of multiple sclerosis: lessons from the bedside for the bench. Clin Neurol Neurosurg 2004; 106: 270–4.
, , .
et al. Alemtuzumab vs. interferon beta-1a in early multiple sclerosis. N Engl J Med 2008; 359: 1786–801.
et al. Pulsed monoclonal antibody treatment and autoimmune thyroid disease in multiple sclerosis. Lancet 1999; 354: 1691–5.
et al. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood 1994; 83: 435–45.
Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets. Nat Med 2000; 6: 443–6.
, , , .
et al. Do oligoclonal bands add information to MRI in first attacks of multiple sclerosis? Neurology 2008; 70(13 Pt 2): 1079–83.
et al. B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N Engl J Med 2008; 358: 676–88.
et al. Rituximab-related viral infections in lymphoma patients. Leuk Lymphoma 2007; 48: 1307–12.
et al. Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the research on adverse drug events and reports project. Blood 2009; 113: 4834–40.
et al. Detection of ectopic B-cell follicles with germinal centers in the meninges of patients with secondary progressive multiple sclerosis. Brain Pathol 2004; 14: 164–74.
et al. Meningeal B-cell follicles in secondary progressive multiple sclerosis associate with early onset of disease and severe cortical pathology. Brain 2007; 130 (Pt 4): 1089–104.
et al. Effect of rituximab on the peripheral blood and cerebrospinal fluid B cells in patients with primary progressive multiple sclerosis. Arch Neurol 2005; 62: 258–64.
et al. Efficacy and Safety of Rituximab in Patients with Primary Progressive Multiple Sclerosis: Results of A Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial. Presented at the World Congress on Treatment and Research in Multiple Sclerosis: 2008 Joint Meeting of the American, European, and Latin America Committees on Treatment and Research in Multiple Sclerosis. Montreal, Quebec, 2008. , ,
et al. An open label study of the effects of rituximab in neuromyelitis optica. Neurology 2005; 64: 1270–2.
et al. Treatment of neuromyelitis optica with rituximab: retrospective analysis of 25 patients. Arch Neurol 2008; 65: 1443–8.
Anti-Tac (daclizumab, Zenapax) in the treatment of leukemia, autoimmune diseases, and in the prevention of allograft rejection: a 25-year personal odyssey. J Clin Immunol 2007; 27: 1–18.
et al. Treatment of noninfectious intermediate and posterior uveitis with the humanized anti-Tac mAb: a phase I/II clinical trial. Proc Natl Acad Sci U S A 1999; 96: 7462–6.
The use of antibodies against the IL-2 receptor in transplantation. Curr Opin Immunol 1998; 10: 507–12.
et al. Regulatory CD56 (bright) natural killer cells mediate immunomodulatory effects of IL-2Ralpha-targeted therapy (daclizumab) in multiple sclerosis. Proc Natl Acad Sci U S A 2006; 103: 5941–6.
Treatment of multiple sclerosis with an anti-interleukin-2 receptor monoclonal antibody. Ann Neurol 2004; 56: 864–7.
, , , .
et al. Humanized anti-CD25 (daclizumab) inhibits disease activity in multiple sclerosis patients failing to respond to interferon beta. Proc Natl Acad Sci U S A 2004; 101: 8705–8.
et al. Effect of anti-CD25 antibody daclizumab in the inhibition of inflammation and stabilization of disease progression in multiple sclerosis. Arch Neurol 2009; 66: 483–9.
et al. Daclizumab phase II trial in relapsing and remitting multiple sclerosis: MRI and clinical results. Neurology 2007; 69: 785–9.
et al. Daclizumab in the Treatment of Patients with Multiple Sclerosis. Presented at the 59th Annual Meeting of the American Academy of Neurology. Boston, MA, 2007. , ,
et al. Preliminary CHOICE results: a Phase 2, randomised, double-blind, placebo-controlled multicentre study of subcutaneous daclixumab in patients with active, relapsing forms of multiple sclerosis on interferon B. Presented at the 23rd Congress of the European Committee for the Treatment and Research in Multiple Sclerosis. Prague, Czech Republic, 2007. , ,
FTY720: sphingosine 1-phosphate receptor-1 in the control of lymphocyte egress and endothelial barrier function. Am J Transplant 2004; 4: 1019–25.
, , .
et al. FTY720 therapy exerts differential effects on T cell subsets in multiple sclerosis. Neurology 2008; 71: 1261–7.
et al. Amelioration of experimental autoimmune encephalomyelitis in Lewis rats by FTY720 treatment. J Pharmacol Exp Ther 2003; 305: 70–7.
et al. Sphingosine 1-phosphate receptor agonists attenuate relapsing-remitting experimental autoimmune encephalitis in SJL mice. J Neuroimmunol 2004; 153: 108–21.
et al. FTY720 modulates human oligodendrocyte progenitor process extension and survival. Ann Neurol 2008; 63: 61–71.
et al. Oral fingolimod (FTY720) for relapsing multiple sclerosis. N Engl J Med 2006; 355: 1124–40.
et al. Oral Fingolimod (FTY720) Versus Interferon Beta-1a in Relapsing Remitting Multiple Sclerosis: Results from a Phase III Study (TRANSFORMS). Presented at the 61st Annual Meeting of the American Academy of Neurology (AAN). Seattle, WA, 2009. , ,
et al. Hemorrhaging focal encephalitis under fingolimod (FTY720) treatment: a case report. Neurology 2009; 72: 1022–4.
Specific toxicity of 2-chlorodeoxyadenosine toward resting and proliferating human lymphocytes. Blood 1983; 62: 737–43.
, , , .
et al. Cladribine in treatment of chronic progressive multiple sclerosis. Lancet 1994; 344: 9–13.
Cladribine MRI Study Group. Cladribine and progressive MS: clinical and MRI outcomes of a multicenter controlled trial. Neurology 2000; 54: 1145–55.
, , ,
et al. A double-blind, placebo-controlled, randomized trial of cladribine in relapsing-remitting multiple sclerosis. Proc Assoc Am Physicians 1999; 111: 35–44.
Clinical Efficacy of Cladribine Tablet Therapy in Patients with Relapsing-Remitting Multiple Sclerosis: Results from the CLARITY Study, a 96-week, Phase III, Double-Blind, Placebo-Controlled Trial. Presented at the 61st Annual Meeting of the American Academy of Neurology (AAN). Seattle, WA, 2009. .
Spotlight on teriflunomide. Int MS J 2008; 15: 62–8.
, , .
Leflunomide: an immunomodulatory drug for the treatment of rheumatoid arthritis and other autoimmune diseases. Immunopharmacology 2000; 47: 273–89.
, , .
et al. Teriflunomide reduces behavioral, electrophysiological, and histopathological deficits in the Dark Agouti rat model of experimental autoimmune encephalomyelitis. J Neurol 2009; 256: 89–103.
Modulation of effector cell functions in experimental autoimmune encephalomyelitis by leflunomide – mechanisms independent of pyrimidine depletion. J Leukoc Biol 2004; 76: 950–60.
, , , .
et al. A Phase II study of the safety and efficacy of teriflunomide in multiple sclerosis with relapses. Neurology 2006; 66: 894–900.
et al. The efficacy and safety of leflunomide in patients with active rheumatoid arthritis: a five-year followup study. Arthritis Rheum 2003; 48: 1513–20.
et al. A comparison of the efficacy and safety of leflunomide and methotrexate for the treatment of rheumatoid arthritis. Rheumatology (Oxford) 2000; 39: 655–65.
et al. The new orally active immunoregulator laquinimod (ABR-215062) effectively inhibits development and relapses of experimental autoimmune encephalomyelitis. J Neuroimmunol 2002; 130: 163–72.
et al. Treatment with laquinimod reduces development of active MRI lesions in relapsing MS. Neurology 2005; 64: 987–91.
et al. Effect of laquinimod on MRI-monitored disease activity in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study. Lancet 2008; 371: 2085–92.
et al. Oral fumaric acid esters for the treatment of active multiple sclerosis: an open-label, baseline-controlled pilot study. Eur J Neurol 2006; 13: 604–10.
et al. Acetylcarnitine induces heme oxygenase in rat astrocytes and protects against oxidative stress: involvement of the transcription factor Nrf2. J Neurosci Res 2005; 79: 509–21.
et al. Stabilization of Nrf2 by tBHQ confers protection against oxidative stress-induced cell death in human neural stem cells. Toxicol Sci 2005; 83: 313–28.
et al. Vacuolar leukoencephalopathy with widespread astrogliosis in mice lacking transcription factor Nrf2. Am J Pathol 2007; 170: 2068–76.
et al. Selective stimulation of T helper 2 cytokine responses by the anti-psoriasis agent monomethylfumarate. Eur J Immunol 1996; 26: 2067–74.
Dimethylfumarate is an inhibitor of cytokine-induced E-selectin, VCAM-1, and ICAM-1 expression in human endothelial cells. Biochem Biophys Res Commun 1997; 234: 19–23.
, , , .
et al. Efficacy and safety of oral fumarate in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study. Lancet 2008; 372: 1463–72.
Alpha 4 integrin antagonists. Curr Pharm Des 2002; 8: 1229–53.
et al. Disseminated lesions at presentation in patients with optic neuritis. J Neurol Neurosurg Psychiatry 1986; 49: 124–7.
et al. Paraclinical tests in acute-onset optic neuritis: basal data and results of a short follow-up. Acta Neurol Scand 1991; 84: 231–6.
Long-term follow-up of acute partial transverse myelopathy. Neurology 1992; 42: 250–2.
, , .
et al. Comparison of MRI criteria at first presentation to predict conversion to clinically definite multiple sclerosis. Brain 1997; 120 (Pt 11): 2059–69.
et al. Modification of MRI criteria for multiple sclerosis in patients with clinically isolated syndromes. J Neurol Neurosurg Psychiatry 2006; 77: 830–3.
et al. Baseline MRI predicts future attacks and disability in clinically isolated syndromes. Neurology 2006; 67: 968–72.
Axonal pathology in multiple sclerosis: relationship to neurologic disability. Curr Opin Neurol 1999; 12: 295–302.
, , .
et al. A longitudinal study of brain atrophy and cognitive disturbances in the early phase of relapsing-remitting multiple sclerosis. J Neurol Neurosurg Psychiatry 2001; 70: 773–80.
et al. Acute axonal damage in multiple sclerosis is most extensive in early disease stages and decreases over time. Brain. 2002; 125 (Pt 10): 2202–12.
et al. Disability and T2 MRI lesions: a 20-year follow-up of patients with relapse onset of multiple sclerosis. Brain 2008; 131 (Pt 3): 808–17.
et al. Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group. N Engl J Med 2000; 343: 898–904.
et al. CHAMPIONS EXTENSION Study: 10-Year Follow-up After a Clinically Isolated Syndrome (CIS) Involving High-Risk Patients. Abstract from the 61st Annual Meeting of the American Academy of Neurology (AAN). Seattle, WA, 2009. Abstract No: P06.137. , ,
et al. Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study. Lancet 2001; 357: 1576–82.
et al. Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes. Neurology 2006; 67: 1242–9.
et al. Recombinant interferon beta or glatiramer acetate for delaying conversion of the first demyelinating event to multiple sclerosis. Cochrane Database Syst Rev 2008, Issue 2: CD005278.
Treatment with Glatiramer Acetate Delays Conversion to Clinically Definite Multiple Sclerosis (CDMS) in Patients with Clinically Isolated Syndromes (CIS). Presented at the American Academy of Neurology (AAN) 60th Annual Meeting. Chicago, IL, 2008. , .
et al. Change in MS-related disability in a population-based cohort: a 10-year follow-up study. Neurology 2004; 62: 51–9.
European Study Group on interferon beta-1b in secondary progressive MS. Placebo-controlled multicentre randomised trial of interferon beta-1b in treatment of secondary progressive multiple sclerosis. Lancet 1998; 352: 1491–7.
Interferon beta-1b in secondary progressive MS: results from a 3-year controlled study. Neurology 2004; 63: 1788–95.
, , , .
SPECTRIMS Study Group. Randomized controlled trial of interferon- beta-1a in secondary progressive MS: Clinical results. Neurology 2001; 56: 1496–504.
et al. Benefit of interferon beta-1a on MSFC progression in secondary progressive MS. Neurology 2002; 59: 679–87.
et al. Interferon beta-1a in primary progressive MS: an exploratory, randomized, controlled trial. Neurology 2003; 60: 44–51.
Overview of European pilot study of interferon beta-Ib in primary progressive multiple sclerosis. Mult Scler 2004;10 (Suppl. 1): S62; discussion-4.
et al. Glatiramer acetate in primary progressive multiple sclerosis: results of a multinational, multicenter, double-blind, placebo-controlled trial. Ann Neurol 2007; 61: 14–24.
A phase II trial of mitoxantrone in patients with primary progressive multiple sclerosis (abstract). Neurology 2004; 000: A99. , , .
et al. Intravenous immunoglobulin in primary and secondary chronic progressive multiple sclerosis: a randomized placebo controlled multicentre study. Mult Scler 2007; 13: 1107–17.
et al. Intravenous immunoglobulin in secondary progressive multiple sclerosis: randomised placebo-controlled trial. Lancet 2004; 364: 1149–56.
et al. Autologous stem cell transplantation for progressive multiple sclerosis: update of the European Group for blood and marrow transplantation autoimmune diseases working party database. Mult Scler 2006; 12: 814–23.